In progress

Human papillomavirus (HPV) is responsible for the most common sexually transmitted infection that can cause serious damage to cervical cancer. In case of precancerous or advanced lesions, surgical removal of diagnosed or total genital lesions is recommended. Unfortunately, there is a recurrence of cancer after a few years. It is therefore urgent to develop an innovative treatment to eliminate these precancerous lesions. We propose a new RNA-based therapeutic strategy targeting both viral proteins and genes involved in the development of precancerous cells. The originality of this project lies in the synthesis of nanovectors based on porous silicon (SiPo) biocompatible, to encapsulate these RNA. This interdisciplinary project brings together GREMAN (INSA-CVL/ U.Tours/ CNRS) for the development of innovative nanovectors based on SiPo and the Centre de Biophysique Moléculaire (CBM CNRS/ Orléans) for the development of therapeutic RNA.

Project benefits

There are no benefits for this project at this time

People involved in the project

Project leader

No member partner


Information of the project

Start of the project on24 / 04 / 2024

Strategic business lines

Électronique : matériaux, composants et sous-systèmes

Referent of the project

Chargé de projets innovants

07 86 53 38 74


Centre-Val de Loire